Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desloratadine + oxybutynin
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Desloratadine + oxybutynin is a **combination of two active pharmaceutical ingredients**: desloratadine, a long-acting, non-sedating antihistamine (selective H1-receptor antagonist), and oxybutynin, an antimuscarinic/anticholinergic agent that inhibits muscarinic receptors to relieve muscle spasms of the bladder. This combination has been studied in a short-term clinical trial for the treatment of **seasonal allergic rhinitis with post-nasal drip**[1]. The combination is intended to address both the allergic component (via desloratadine's histamine H1 receptor antagonism) and the secretory/musculoskeletal aspect (via oxybutynin's antimuscarinic activity)[1].
- Other names
- Desloratadine and OxybutyninOxybutynin and Desloratadine
02
Targets
CHRM3 (M3)M1 (Muscarinic acetylcholine receptor M1)ButyrylcholinesteraseCHRM2 (M2)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on desloratadine + oxybutynin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desloratadine + oxybutynin.